Kenneth Rose, Ph.D.

Kenneth Rose, Ph.D. has extensive work experience in the pharmaceutical and medical research field. Kenneth is currently the Director of Translational Science at MindImmune Therapeutics, Inc. where they lead the team in developing novel therapeutics. Prior to that, they served as the Chief Scientific Officer at Alcinous Pharmaceuticals.

Before transitioning to industry, Dr. Rose worked as a Research Fellow in Neurology at Massachusetts General Hospital from 2019 to 2023. During this time, they focused on neuroinflammation modulation in models of Alzheimer's disease.

Dr. Rose's educational background includes being a Ph.D. candidate in Neuroscience at the University of Rhode Island. Kenneth also served as a Chemistry Teaching Assistant at the university from 2016 to 2019. Their research as a Ph.D. candidate involved leading projects to discover and develop potential therapeutics derived from terrestrial natural products.

Overall, Dr. Kenneth Rose has shown expertise and leadership in translational science, neurology research, and pharmaceutical development.

Kenneth Rose, Ph.D. obtained their Bachelor of Science (B.S.) degree in Psychology from the University of Lynchburg between 2011 to 2015. Following that, they went on to pursue their Doctor of Philosophy (Ph.D.) in Interdisciplinary Neuroscience at the University of Rhode Island from 2015 to 2019.